<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656301</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#7950</org_study_id>
    <nct_id>NCT04656301</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder</brief_title>
  <official_title>Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>COMPASS Pathways</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded&#xD;
      to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with&#xD;
      a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will&#xD;
      be conducted over a 3 month period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot study, up to 12 adult outpatients with body dysmorphic disorder that has not&#xD;
      responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated&#xD;
      openly with a single oral dose of psilocybin. Procedures will follow those previously&#xD;
      established in depression studies of psilocybin. Patients will receive intensive preparation&#xD;
      and support from two therapists, including 8-9 hours accompanying the patient on the day of&#xD;
      medication administration in the Biological Studies Unit of New York State Psychiatric&#xD;
      Institute. Followup visits to monitor safety and clinical outcome will be conducted at day 1,&#xD;
      week1, and months 1,2, and 3 post-administration. Resting state function magnetic resonance&#xD;
      imaging will be conducted prior to and one day after psilocybin administration to assess the&#xD;
      effect of medication on brain circuits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Dysmorphic Disorder Modification of the Yale-Brown Obsessive Compulsive Disorder Scale</measure>
    <time_frame>From baseline (day -1) up to 3 months post-dose</time_frame>
    <description>The Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) is a 12-item, semi-structured, rater-administered measure that assesses body dysmorphic disorder severity during the past week. Scores for each item range from 0 (no symptoms) to 4 (extreme symptoms); the total score ranges from 0 to 48, with higher scores reflecting more severe symptoms.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Body Dysmorphic Disorders</condition>
  <arm_group>
    <arm_group_label>Psilocybin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Psilocybin 25mg p.o.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute</description>
    <arm_group_label>Psilocybin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body dysmorphic disorder of at least moderate severity, non-delusional subtype, for &gt;6&#xD;
             months&#xD;
&#xD;
          -  History of intolerance of, or nonresponse to, a prior adequate trial of a serotonin&#xD;
             reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)&#xD;
&#xD;
          -  Currently in psychotherapy (other than cognitive behavioral therapy (CBT) for body&#xD;
             dysmorphic disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current major depressive disorder of greater than moderate severity&#xD;
&#xD;
          -  Other significant psychiatric or medical comorbidity or conditions that could&#xD;
             interfere with safety of participation or interpretation of outcomes&#xD;
&#xD;
          -  Use of: investigational medication within 3 months of baseline; depot antipsychotic&#xD;
             within 6 months of baseline; serotonergic medication within 2 weeks of baseline (6&#xD;
             weeks for fluoxetine).&#xD;
&#xD;
          -  Females who are pregnant, breastfeeding, or sexually active and not willing to use&#xD;
             adequate contraception&#xD;
&#xD;
          -  Enrollment in any investigational drug or device study in past 30 days&#xD;
&#xD;
          -  Prior adverse effects from psilocybin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franklin Schneier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Foundation for Mental Hygiene/NY State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Gomez, BA</last_name>
    <phone>6467748113</phone>
    <email>gloria.gomez@nyspi.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York State Psychiatric Institute, 1051 Riverside Drive</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Gomez</last_name>
      <phone>646-450-4572</phone>
      <email>gloria.gomez@nyspi.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Franklin Schneier</investigator_full_name>
    <investigator_title>Professor of Clinical Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Dysmorphic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

